Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

From Biomarkers to Treatment: The New Need-to-Know in Early Breast Cancer
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: June 8, 2022 Expiration: June 7, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.
Heather McArthur, MD, MPH
Program Director
Jennifer K. Litton, MD
Rita Nanda, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply guidelines and expert recommendations for germline BRCA testing in patients with early-stage breast cancer
  • Develop genetic testing and risk assessment strategies that incorporate expert guidance to identify all patient subgroups with EBC at high risk for recurrence
  • Discuss with patients how their risk of progression affects prognosis and therapeutic planning
  • Identify patients with EBC most likely to benefit from recently approved neoadjuvant/adjuvant targeted or immunotherapy agents
  • Plan adjuvant therapy using PARP inhibitor, immune checkpoint inhibitor, and/or CDK4/6 inhibitors for select patients with EBC
  • Manage treatment-related adverse events in the early-stage breast cancer setting associated with new treatment options to improve adherence, improve patient experience, and optimize outcomes

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Heather McArthur, MD, MPH

Associate Professor
Department of Medicine
Medical Director, Breast Oncology
Samuel Oschin Comprehensive Cancer Center
Cedars-Sinai Medical Center
Los Angeles, California

Heather McArthur, MD, MPH, has disclosed that she has served on advisory boards for AstraZeneca, Bristol-Myers Squibb, Crown Bioscience, Daiichi Sankyo, Gilead Sciences, Immunomedics, Lilly, Merck, Pfizer, Puma Biotech, and Seattle Genetics and has received funds for research support paid to her institution from Bristol-Myers Squibb and Merck.

Faculty

Jennifer K. Litton, MD

Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jennifer K. Litton, MD, has disclosed that she has received funds for research support from AstraZeneca, EMD-Serono, Genentech, Merck, Pfizer, and Zenith.
Rita Nanda, MD

Associate Professor of Medicine
Director, 
Breast Oncology
Section of Hematology/Oncology
Department of Medicine
The University of Chicago
Chicago, Illinois

Rita Nanda, MD, has disclosed that she has received funds for research support from Arvinas, AstraZeneca, Celegent, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, Seattle Genetics, and Taiho and has served on advisory boards for AstraZeneca, BeyondSpring, Cardinal Health, Fuji Film, Immunomedics/Gilead Infinity, iTeos, MacroGenics, Merck, OBI, OncoSec, and Seattle Genetics.

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Jill Sakai, PhD

Editorial Contributor

Jill Sakai, PhD has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for medical oncologists, pathologists, and other healthcare professionals who care for patients with breast cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new and emerging therapies into individualized treatment plans for early-stage breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 08, 2022, through June 07, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

From Biomarkers to Treatment: The New Need-to-Know in Early Breast Cancer
  • CME

Loading...
In this on-demand webcast from a live symposium, experts Heather McArthur, MD, MPH; Jennifer K. Litton, MD; and Rita Nanda, MD discuss the most up-to-date guidance on managing early-stage breast cancer.
Heather McArthur, MD, MPH
Program Director
Jennifer K. Litton, MD
Rita Nanda, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: June 8, 2022 Expiration: June 7, 2023

Related Content

Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)

Heather McArthur, MD, MPH
Program Director
Released: August 4, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Downloadable slideset from a live webinar presented by Jamie Carroll, MSN on managing adverse events and promoting adherence to CDK4/6 and PI3K inhibitors, from Clinical Care Options (CCO)

Robert T. Carroll, PhD(c), RN, ACRN Released: July 26, 2022

Downloadable slideset from a live webinar presented by Sarah Hurvitz, MD, on selecting and sequencing targeted therapy for HR+/HER2- breast cancer, from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: July 26, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Lilly
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings